NASDAQ · ME
Healthcare · Medical - Diagnostics & Research
$0.61
Up+$0.61 (+0.00%)
Updated Aug 15, 2026, 4:58 AM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
ME does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
The latest Smart Investors Daily articles mentioning ME.
ME research
Company profile and research snapshot.
23andMe Holding Co. operates as a consumer genetics testing company. It operates through two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications based on genetic testing of a saliva sample through its spit kit. The Therapeutics segment focuses on the drug development; and discovery and development of novel therapies to improve patient lives across various therapeutic areas, including oncology, respiratory, and cardiovascular diseases, as well as offers out-licensing of intellectual property associated with identified drug targets related to drug candidates under clinical development. It has a collaboration agreement with GlaxoSmithKline Intellectual Property (No.3) Limited to leverage genetic insights to validate, develop, and commercialize drugs. The company was founded in 2006 and is headquartered in South San Francisco, California.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Apr 16, 2024 | Citigroup | Neutral | — |
| Aug 10, 2023 | Citigroup | Buy | — |
| May 26, 2023 | Citigroup | Neutral | — |
| May 26, 2023 | Credit Suisse | Outperform | — |
| Nov 29, 2022 | Berenberg | Buy | — |
No generated briefing is available yet.
Benzinga · Jul 16, 2026
Trump imposes 25% tariffs on most Brazilian imports under Section 301, with duties potentially rising to 37.5% next week.
GlobeNewswire Inc. · Mar 26, 2025
23andMe Holding Co. has filed for Chapter 11 bankruptcy and received court approval for its 'first day' motions, including authorization to pay employee wages and enter into a $35 million debtor-in-possession financing facility. The company plans to sell substantially all of its assets through a Chapter 11 plan or Section 363 sale process.
GlobeNewswire Inc. · Mar 26, 2025
DeleteMe, a privacy service, is offering to help 23andMe users remove their sensitive genetic data from the platform as the company faces financial challenges and potential bankruptcy. This service aims to provide individuals with peace of mind about their data privacy.
GlobeNewswire Inc. · Dec 20, 2024
Marisa Brahney, an Emmy-Award winning TV host and lifestyle expert, shares her list of must-have holiday gifts, including stylish footwear from Famous Footwear, affordable and unique gifts from Big Lots, personalized DNA kits from 23andMe, and gentle skincare products from Pears.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning ME.
No results
No recent SID articles mention ME.
